- NACDS supports bill to curb Rx abuse, safeguard patients
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- NACDS RxImpact shines spotlight on pharmacists' increasing role in delivery of healthcare services
- ROUNDTABLE: Pharmacy’s future in sync with technology
- Insurance rollout shows pharmacies and NACDS in action
WHITEHOUSE STATION, N.J. — The Food and Drug Administration has accepted a regulatory approval application for a drug to treat Type 2 diabetes made by Merck, the drug maker said Tuesday.
Merck announced the acceptance of its application for extended-release Janumet, which combines in a single pill the active ingredient sitagliptin with extended-release metformin, a drug commonly prescribed for Type 2 diabetes.
Janumet belongs to the class known as DPP-4 inhibitors, which also includes Onglyza (saxagliptin), made by Bristol-Myers Squibb and AstraZeneca. Merck also makes an immediate-release formulation of the drug.